ARGOS

• Research type

  Research Study

• Full title

  Acute Respiratory Infections Global Outpatient Study

• IRAS ID

  308801

• Contact name

  Patrick Moore

• Contact email

  patrick.moore@dorsetgp.nhs.uk

• Sponsor organisation

  Actelion Pharmaceuticals Ltd.

• Clinicaltrials.gov Identifier

  NCT05148780

• Duration of Study in the UK

  2 years, 11 months, 16 days

• Research summary

  Lower respiratory tract infections (LRTIs) are a major cause of mortality and morbidity worldwide with 2.3 million deaths in 2016 alone among all age groups, making it the sixth leading cause of mortality. Older adults, immunocompromised or chronically ill patients are at increased risk for severe outcomes from respiratory infections.
  
  The current study aims to assess the burden of respiratory syncytial virus (RSV) infections among adult patients presenting in outpatient settings, who are at high risk of complications or progression to severe disease due to their age or pre-existing comorbidities. Regional data from the United States (US), Europe, Middle East and Asia (EMEA) and Asia-Pacific (APAC) will provide evidence on local RSV morbidity, mortality, medical resource utilization (MRU), standard of care, and quality of life in adult patients. A subset of patients positive for influenza virus and/or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) will also be enrolled, to allow for a comparative assessment of disease burden between the 3 viral respiratory pathogens.

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  22/YH/0024

• Date of REC Opinion

  17 Jun 2022

• REC opinion

  Further Information Favourable Opinion